Possibilities of modern insulin therapy in achieving the best therapeutic results in patients with diabetes mellitus

May 13, 2018
767
Specialities :
Resume

The article presents data on the main problems of managing patients with diabetes mellitus. The clinical cases described the difficulties with of insulin therapy use, which patients with diabetes are facing, and the ways to overcome them are presented. It has been shown that selection of insulin and its doses should be individualized, taking into account the duration of action, the risk of side effects and the ease of use. The possibilities of correction and optimization of the insulin therapy have been demonstrated in order to provide target indicators of glycemic control, ease of use for the patient, minimization of the risk of complications and therefore — increase of compliance and ultimately achieve the best therapeutic results.

S.L. Skorikova

Key words: diabetes mellitus, insulin, insulin glargine, long-acting insulin analogues, insulin therapy.

Published: 04.05.2018

References:

  • Bezdetko N.V. (2016) Biosimilyaryi analogov insulina: chto neobhodimo znat klinitsistu. Ukr. med. chasopis, 1(111): 35–41 (http://www.umj.com.ua/article/93252).
  • Klimontov V.V., Myakina N.E. (2015) Biosimilyaryi analogov insulina: chto myi dolzhnyi o nih znat. Effekt. farmakoter. endokrinol., 1(7): http://www.umedp.ru/articles/biosimilyary_analogov_insulina_chto_my_dolzhny_o_nikh_znat.html.
  • Ministerstvo okhorony zdorovia Ukrainy (2013) Nakaz MOZ Ukrainy vid 04.01.2013 r. № 3 «Pro vnesennia zmin do nakazu MOZ Ukrainy vid 29.06.2003 r. № 358 «Pro zatverdzhennia formy ta opysu reiestratsiinoho posvidchennia na likarskyi zasib» (http://zakon5.rada.gov.ua/laws/show/z0162-13).
  • Ministerstvo okhorony zdorovia Ukrainy (2015) Nakaz MOZ vid 23.07.2015 r. № 460 «Pro vnesennia zmin do Poriadku provedennia ekspertyzy reiestratsiinykh materialiv na likarski zasoby, shcho podaiutsia na derzhavnu reiestratsiiu (perereiestratsiiu), a takozh ekspertyzy materialiv pro vnesennia zmin do reiestratsiinykh materialiv protiahom dii reiestratsiinoho posvidchennia ta zatverdzhennia Poriadku perevirky materialiv, dodanykh do zaiavy pro derzhavnu reiestratsiiu okremykh likarskykh zasobiv, shchodo yikh obsiahu» (http://www.moz.gov.ua/ua/portal/dn_20150723_0460.html).
  • Poltorak V.V., Karachentsev Yu.I., Gorshunskaya M.Yu. (2003) Insulin glargin (Lantus) — pervyiy bespikovyiy bazalnyiy dlitelno deystvuyuschiy insulin: farmakokinetika, farmakodinamika, perspektivnost klinicheskogo primeneniya. Ukr. med. chasopis, 2(34): 43–58 (http://www.umj.com.ua/article/1217).
  • Poltorak V.V., Sokolova L.K., Gorshunskaya M.Yu. (2016) Insulin Tozheo SoloStar: osnovnyie svoystva i novyie vozmozhnosti v dostizhenii glikemicheskogo kontrolya. med. chasopis, 1(111): 43–48 (http://www.umj.com.ua/article/93109).
  • Ali M.K., Bullard K.M., Saaddine J.B. et al. (2013) Achievement of goals in U.S. diabetes care, 1999–2010. N. Engl. J. Med., 368(17): 1613–1624.
  • American Diabetes Association (2017) Standards of Medical Care in Diabetes 2017. Diabetes Care, 40(Suppl. 1): 135.
  • Becker R.H., Dahmen R., Bergmann K. et al. (2015) New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care, 38(4): 637–643.
  • European Medicines Agency (2015) Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. EMEA, London, 12 p.
  • Fernandez A., Schillinger D., Warton E.M. et al. (2011) Language barriers, physician-patient language concordance, and glycemic control among insured Latinos with diabetes: the Diabetes Study of Northern California (DISTANCE). J. Gen. Intern. Med., 26(2): 170–176.
  • International Hypoglycaemia Study Group (2017) Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 40: 155–157.
  • Kerr E.A., Heisler M., Krein S.L. et al. (2007) Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients’ treatment priorities and self-management? J. Gen. Intern. Med., 22(12): 1635–1640.
  • Monami M., Marchionni N., Mannucci E. (2009) Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes: a meta-analysis. Diabetes Obes. Metab., 11: 372–378.
  • Skyler J.S., Bakris G.L., Bonifacio E. et al. (2017) Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 66(2): 241–255.
  • Sutton G., Minguet J., Ferrero C., Bramlage P. (2014) U300, a novel long-acting insulin formulation. Expert Opin Biol. Ther., 14(12): 1849–1860.
  • TRIAD Study Group (2010) Health systems, patients factors, and quality of care for diabetes: a synthesis of findings from the TRIAD study. Diabetes Care, 33(4): 940–947.
  • Tricco A.C., Ashoor H.M., Antony J. et al. (2014) Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ, 349: g5459.
  • Vardi M., Jacobson E., Nini A., Bitterman H. (2008) Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst. Rev., 3: CD006297.
  • World Health Organization (2009) Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO, Geneva, 41 p.